BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 15777603)

  • 1. Salmeterol HFA is as effective as salmeterol CFC in children and adults with persistent asthma.
    Chopra N; Williams M; Rimmer M; Kahl L; Jenkins M;
    Respir Med; 2005 Apr; 99 Suppl A():S1-S10. PubMed ID: 15777603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
    Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects.
    Kempsford R; Handel M; Mehta R; De Silva M; Daley-Yates P
    Respir Med; 2005 Apr; 99 Suppl A():S11-9. PubMed ID: 15777604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and performance of a new hydrofluoroalkane (HFA 134a)-based metered dose inhaler (MDI) of salmeterol.
    Peyron ID; Britto IL; Benissan LB; Tardieu BZ
    Respir Med; 2005 Apr; 99 Suppl A():S20-30. PubMed ID: 15777605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and safety of fluticasone propionate 250 microg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French study group.
    Tonnel AB; Bons J; Legendre M; Prud'Homme A; Bugnas B; Evano-Celli I; Stuart AM
    Respir Med; 2000 Jun; 94 Suppl B():S29-34. PubMed ID: 10919683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group.
    Ayres JG; Millar AB; Sykes AP
    Respir Med; 2000 Jun; 94 Suppl B():S42-50. PubMed ID: 10919685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients.
    Langley SJ; Sykes AP; Batty EP; Masterson CM; Woodcock A
    Ann Allergy Asthma Immunol; 2002 May; 88(5):488-93. PubMed ID: 12027070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching patients with asthma from chlorofluorocarbon (CFC) albuterol to hydrofluoroalkane-134a (HFA) albuterol.
    Bronsky E; Ekholm BP; Klinger NM; Colice GL
    J Asthma; 1999; 36(1):107-14. PubMed ID: 10077140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma.
    Bateman ED; Silins V; Bogolubov M
    Respir Med; 2001 Feb; 95(2):136-46. PubMed ID: 11217910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of reducing the fine-particle mass of salmeterol from metered-dose inhalers on bronchodilatation and bronchoprotection against methacholine challenge: a randomized, placebo-controlled, double-blind, crossover study.
    Langley SJ; Allen D; McDonnell B; Wheeler N; Sharma RK; Sykes A; Woodcock A
    Clin Ther; 2005 Jul; 27(7):1004-12. PubMed ID: 16154479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fenoterol hydrobromide delivered via HFA-MDI or CFC-MDI in patients with asthma: a safety and efficacy comparison.
    Goldberg J; Böhning W; Schmidt P; Freund E
    Respir Med; 2000 Oct; 94(10):948-53. PubMed ID: 11059947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic equivalence of inhaled beclomethasone dipropionate with CFC and non-CFC (HFA 134a) propellants both delivered via the Easibreathe inhaler for the treatment of paediatric asthma.
    Farmer IS; Middle M; Savic J; Perri VL; Herdman MJ
    Respir Med; 2000 Jan; 94(1):57-63. PubMed ID: 10714480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of fluticasone propionate 44 microg/salmeterol 21 microg administered in a hydrofluoroalkane metered-dose inhaler as an initial asthma maintenance treatment.
    Nelson HS; Wolfe JD; Gross G; Greos LS; Baitinger L; Scott C; Dorinsky P
    Ann Allergy Asthma Immunol; 2003 Sep; 91(3):263-9. PubMed ID: 14533658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical comparability between the CFC and HFA budesonide pressurised metered-dose inhalers in paediatric patients with asthma: a randomised controlled trial.
    Escribano A; Tutuncu A; Löhr I; Carlholm M; Polanowski T
    Curr Med Res Opin; 2006 Jun; 22(6):1085-92. PubMed ID: 16846541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placebo-controlled, comparative study of the efficacy and safety of triamcinolone acetonide inhalation aerosol with the non-CFC propellant HFA-134a in patients with asthma. Azmacort HFA Clinical Study Group.
    Jacobson K; Chervinsky P; Noonan M; Kane RE; Banerji D; Uryniak T
    Ann Allergy Asthma Immunol; 1999 Oct; 83(4):327-33. PubMed ID: 10541425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy and safety of fluticasone propionate 1 mg per day administered via a HFA 134a pressurized metered dose inhaler to patients with moderate to severe asthma. International study group.
    Perruchoud AP; Lundback B; Yigla M; Sykes AP
    Respir Med; 2000 Jun; 94 Suppl B():S35-41. PubMed ID: 10919684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids.
    You-Ning L; Humphries M; Du X; Wang L; Jiang J
    Int J Clin Pract; 2005 Jul; 59(7):754-9. PubMed ID: 15963199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma.
    Pearlman DS; Peden D; Condemi JJ; Weinstein S; White M; Baitinger L; Scott C; Ho SY; House K; Dorinsky P
    J Asthma; 2004; 41(8):797-806. PubMed ID: 15641629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extrafine aerosol in asthma patients.
    Corren J; Nelson H; Greos LS; Bensch G; Goldstein M; Wu J; Wang S; Newman K
    Ann Allergy Asthma Immunol; 2001 Nov; 87(5):405-11. PubMed ID: 11730183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects on lung function, symptoms, and bronchial hyperreactivity of low-dose inhaled beclomethasone dipropionate given with HFA-134a or CFC propellant.
    Woodcock A; Williams A; Batty L; Masterson C; Rossetti A; Cantini L
    J Aerosol Med; 2002; 15(4):407-14. PubMed ID: 12581507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.